Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Abnormal hippocampal neurogenesis in Parkinson’s disease: relevance to a new therapeutic target for depression with Parkinson’s disease
Juhee Lim, Yeojin Bang, Hyun Jin Choi
Archives of Pharmacal Research (2018) Vol. 41, Iss. 10, pp. 943-954
Closed Access | Times Cited: 72

Showing 1-25 of 72 citing articles:

Parkinson's disease, aging and adult neurogenesis: Wnt/β‐catenin signalling as the key to unlock the mystery of endogenous brain repair
Bianca Marchetti, Cataldo Tirolo, Francesca L’Episcopo, et al.
Aging Cell (2020) Vol. 19, Iss. 3
Open Access | Times Cited: 143
Neurogenesis in aging and age-related neurodegenerative diseases
Luka Čulig, Xixia Chu, Vilhelm A. Bohr
Ageing Research Reviews (2022) Vol. 78, pp. 101636-101636
Open Access | Times Cited: 119
The Dialogue Between Neuroinflammation and Adult Neurogenesis: Mechanisms Involved and Alterations in Neurological Diseases
Mobina Amanollahi, Melika Jameie, Arash Heidari, et al.
Molecular Neurobiology (2022) Vol. 60, Iss. 2, pp. 923-959
Closed Access | Times Cited: 110
Neurobiology of depression in Parkinson’s disease: Insights into epidemiology, molecular mechanisms and treatment strategies
Mir Hilal Ahmad, M. Moshahid A. Rizvi, Mansoor Ali, et al.
Ageing Research Reviews (2023) Vol. 85, pp. 101840-101840
Closed Access | Times Cited: 62
Drug treatment strategies for depression in Parkinson disease
Melody Ryan, Courtney V. Eatmon, John T. Slevin
Expert Opinion on Pharmacotherapy (2019) Vol. 20, Iss. 11, pp. 1351-1363
Closed Access | Times Cited: 83
Neurogenic and anti-inflammatory effects of probiotics in Parkinson’s disease: A systematic review of preclinical and clinical evidence
Valentina Leta, К. Ray Chaudhuri, Oliver Milner, et al.
Brain Behavior and Immunity (2021) Vol. 98, pp. 59-73
Closed Access | Times Cited: 57
Impact of Environmental Risk Factors on Mitochondrial Dysfunction, Neuroinflammation, Protein Misfolding, and Oxidative Stress in the Etiopathogenesis of Parkinson’s Disease
Minhong Huang, Alejandra Bargues-Carot, Zainab Riaz, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 18, pp. 10808-10808
Open Access | Times Cited: 56
NOX4 as a critical effector mediating neuroinflammatory cytokines, myeloperoxidase and osteopontin, specifically in astrocytes in the hippocampus in Parkinson's disease
Napissara Boonpraman, Sunmi Yoon, Chae Young Kim, et al.
Redox Biology (2023) Vol. 62, pp. 102698-102698
Open Access | Times Cited: 28
Adult neurogenesis
Ghulam Hussain, Rabia Akram, Haseeb Anwar, et al.
Neural Regeneration Research (2023) Vol. 19, Iss. 1, pp. 6-15
Open Access | Times Cited: 23
Upregulated ECM genes and increased synaptic activity in Parkinson’s human DA neurons with PINK1/ PRKN mutations
Utkarsh Tripathi, Idan Rosh, Ran Ben Ezer, et al.
npj Parkinson s Disease (2024) Vol. 10, Iss. 1
Open Access | Times Cited: 9
Postbiotics as Molecules Targeting Cellular Events of Aging Brain—The Role in Pathogenesis, Prophylaxis and Treatment of Neurodegenerative Diseases
Pola Głowacka, Katarzyna Oszajca, Agnieszka Pudlarz, et al.
Nutrients (2024) Vol. 16, Iss. 14, pp. 2244-2244
Open Access | Times Cited: 9
Recent advances in the pathology of prodromal non-motor symptoms olfactory deficit and depression in Parkinson’s disease: clues to early diagnosis and effective treatment
Yeojin Bang, Juhee Lim, Hyun Jin Choi
Archives of Pharmacal Research (2021) Vol. 44, Iss. 6, pp. 588-604
Open Access | Times Cited: 55
The pathobiological basis of depression in Parkinson disease: challenges and outlooks
K. A. Jellinger
Journal of Neural Transmission (2022) Vol. 129, Iss. 12, pp. 1397-1418
Open Access | Times Cited: 30
Botulinum neurotoxin A ameliorates depressive-like behavior in a reserpine-induced Parkinson’s disease mouse model via suppressing hippocampal microglial engulfment and neuroinflammation
Yang Li, Qiao Yin, Qi Li, et al.
Acta Pharmacologica Sinica (2023)
Open Access | Times Cited: 17
Melatonin/polydopamine nanostructures for collective neuroprotection-based Parkinson's disease therapy
Anup K. Srivastava, Subhasree Roy Choudhury, Surajit Karmakar
Biomaterials Science (2019) Vol. 8, Iss. 5, pp. 1345-1363
Closed Access | Times Cited: 44
TGF-β/Smad3 Signalling Modulates GABA Neurotransmission: Implications in Parkinson’s Disease
Marı́a-Dolores Muñoz, Nerea de la Fuente, Amelia Sánchez‐Capelo
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 2, pp. 590-590
Open Access | Times Cited: 41
The Selective SIK2 Inhibitor ARN-3236 Produces Strong Antidepressant-Like Efficacy in Mice via the Hippocampal CRTC1-CREB-BDNF Pathway
Yue Liu, Wenqian Tang, Chun-Hui Ji, et al.
Frontiers in Pharmacology (2021) Vol. 11
Open Access | Times Cited: 33
Atrophy patterns in hippocampus and amygdala subregions of depressed patients with Parkinson's disease
Mingrui Qu, Bingbing Gao, Yuhan Jiang, et al.
Brain Imaging and Behavior (2024) Vol. 18, Iss. 3, pp. 475-484
Open Access | Times Cited: 6
Cannabinoid Actions on Neural Stem Cells: Implications for Pathophysiology
Rui S. Rodrigues, Diogo M. Lourenço, Sara L. Paulo, et al.
Molecules (2019) Vol. 24, Iss. 7, pp. 1350-1350
Open Access | Times Cited: 40
Silibinin ameliorates depression/anxiety-like behaviors of Parkinson's disease mouse model and is associated with attenuated STING-IRF3-IFN-β pathway activation and neuroinflammation
Xiumin Liu, Wenhui Chen, Chenkang Wang, et al.
Physiology & Behavior (2021) Vol. 241, pp. 113593-113593
Closed Access | Times Cited: 28
Preclinical reserpine models recapitulating motor and non-motor features of Parkinson’s disease: Roles of epigenetic upregulation of alpha-synuclein and autophagy impairment
Yang Li, Qiao Yin, Bing Wang, et al.
Frontiers in Pharmacology (2022) Vol. 13
Open Access | Times Cited: 21
Mood disturbances in Parkinson's disease: From prodromal origins to application of animal models
Shawn Hayley, F. Vahid-Ansari, Sun Hongyu, et al.
Neurobiology of Disease (2023) Vol. 181, pp. 106115-106115
Open Access | Times Cited: 12
Baicalin exerts antidepressant effects through Akt/FOXG1 pathway promoting neuronal differentiation and survival
Ruyi Zhang, Zhongxuan Ma, Kai‐Li Liu, et al.
Life Sciences (2019) Vol. 221, pp. 241-248
Closed Access | Times Cited: 30
Antioxidative role of Traditional Chinese Medicine in Parkinson's disease
Fahim Muhammad, Yan Liu, Yongtao Zhou, et al.
Journal of Ethnopharmacology (2021) Vol. 285, pp. 114821-114821
Closed Access | Times Cited: 27
Ursolic acid enhances autophagic clearance and ameliorates motor and non-motor symptoms in Parkinson’s disease mice model
Yeojin Bang, Yoonjung Kwon, Mihyang Kim, et al.
Acta Pharmacologica Sinica (2022) Vol. 44, Iss. 4, pp. 752-765
Open Access | Times Cited: 17
Page 1 - Next Page

Scroll to top